Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EKSO BIONICS ( (EKSO) ) has provided an announcement.
On September 12, 2025, Ekso Bionics entered into a Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC, securing a $2.0 million loan for working capital and corporate purposes. The agreement includes a 10% interest rate, a maturity date of September 14, 2026, and an option for the lender to convert the loan into equity. This move replaces a previous loan agreement with Banc of California, potentially impacting Ekso Bionics’ financial strategy and stakeholder interests by providing more flexible financing options.
The most recent analyst rating on (EKSO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.
Spark’s Take on EKSO Stock
According to Spark, TipRanks’ AI Analyst, EKSO is a Neutral.
EKSO BIONICS’ overall stock score reflects significant financial challenges, including negative profitability and cash flow issues, which are the most impactful factors. While technical indicators show some neutral momentum, the negative valuation metrics further weigh down the score. Despite some positive developments in strategic partnerships and innovation, these are overshadowed by financial setbacks.
To see Spark’s full report on EKSO stock, click here.
More about EKSO BIONICS
Ekso Bionics Holdings, Inc. operates in the technology industry, focusing on developing and manufacturing exoskeleton solutions that enhance human capabilities. The company primarily serves medical and industrial markets, providing products that assist with mobility and rehabilitation.
Average Trading Volume: 147,520
Technical Sentiment Signal: Sell
Current Market Cap: $10.45M
Learn more about EKSO stock on TipRanks’ Stock Analysis page.